SubHero Banner
Text

Epidiolex® (cannabidiol) – New drug approval

June 25, 2018 - GW Pharmaceuticals and its U.S. subsidiary Greenwich Biosciences announced the FDA approval of Epidiolex (cannabidiol), for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.

Download PDF